Trial Profile
Phase I/II Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 11 Oct 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Cytarabine; Dexamethasone; Idarubicin; Methylprednisolone
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 18 Jun 2020 Status changed from active, no longer recruiting to completed.
- 17 Mar 2020 Planned End Date changed from 1 Jan 2021 to 21 Jun 2020.
- 17 Mar 2020 Planned primary completion date changed from 1 Jan 2020 to 21 Jun 2020.